ASCLETIS' ORAL SMALL MOLECULE GLP-1, ASC30, DEMONSTRATED PLACEBO-ADJUSTED HBA1C REDUCTION OF 1.7% AT 12 WEEKS FROM ITS U.S. PHASE II STUDY IN PARTICIPANTS WITH DIABETES

Reuters · 10/28 23:40

Please log in to view news